论文部分内容阅读
目的探讨托拉塞米联合曲美他嗪对慢性心衰(CHF)患者血浆脑利钠肽(BNP)的影响。方法 120例CHF患者随机均分为3组,分别应用托拉塞米5～20mg/d(A组)、曲美他嗪60mg/d(B组)或托拉塞米联合曲美他嗪(C组)治疗,观察疗效,测定治疗前后血浆BNP水平。结果 C组总有效率为95.0%,显著高于A组的80.0%和B组的77.5%(P<0.05)。C组治疗后血浆BNP水平显著低于A、B组(P<0.05)。结论托拉塞米联合曲美他嗪联合治疗CHF能够显著降低患者的血浆BNP水平,疗效优于单独应用托拉塞米或曲美他嗪。
Objective To investigate the effect of torsemide combined with trimetazidine on plasma brain natriuretic peptide (BNP) in patients with chronic heart failure (CHF). Methods A total of 120 patients with CHF were randomly divided into three groups. Patients were randomly divided into three groups: toratosage 5-20 mg / d (group A), trimetazidine 60 mg / d (group B) or torsemide combined with trimetazidine C group) treatment, observe the effect, determination of plasma BNP levels before and after treatment. Results The total effective rate in group C was 95.0%, which was significantly higher than 80.0% in group A and 77.5% in group B (P <0.05). Plasma BNP levels in group C were significantly lower than those in groups A and B (P <0.05). Conclusions Torsemide combined with trimetazidine in the treatment of CHF can significantly reduce the plasma BNP level in patients with superior efficacy compared with torasemide alone or trimetazidine alone.